Chinese companies TransThera Sciences (Nanjing) Inc. and Akeso Biopharma (HKG: 9926) have formed a strategic research collaboration to advance an open, multi-center Phase II study combining TransThera’s tinengotinib (TT-00420) with Akeso’s cadonilimab or ivonescimab for advanced hepatocellular carcinoma (HCC). The National Medical Products Administration (NMPA) has granted clearance for the study.
Drug Profiles and Mechanisms
Tinengotinib, an FGFR inhibitor, has demonstrated significant anti-tumor activity in cholangiocarcinoma, prostate cancer, breast cancer, and other solid tumors. Cadonilimab, a bispecific antibody (BsAb) targeting both PD-1 and CTLA-4, is approved in China for first-line recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma and recurrent or metastatic cervical cancer after platinum-based chemotherapy failure. Ivonescimab, a PD-1/VEGF BsAb, is registered in China as a first-line treatment for EGFR mutant non-squamous non-small cell lung cancer with disease progression after EGFR-TKI therapy.
Clinical Progress and Collaboration
The collaboration aims to evaluate the safety and efficacy of combining tinengotinib with either cadonilimab or ivonescimab in patients with advanced HCC. This combination therapy represents a novel approach to addressing unmet medical needs in HCC treatment, leveraging the unique mechanisms of each drug to potentially enhance therapeutic outcomes.-Fineline Info & Tech
Leave a Reply